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dystemic Inflammation Induces Acute Behavioral and
ognitive Changes and Accelerates
eurodegenerative Disease
olm Cunningham, Suzanne Campion, Katie Lunnon, Carol L. Murray, Jack F.C. Woods,
obert M.J. Deacon, J. Nicholas P. Rawlins, and V. Hugh Perry
ackground: Chronic neurodegeneration results in microglial activation, but the contribution of inflammation to the progress of neuro-
egeneration remains unclear. We have shown thatmicroglia express low levels of proinflammatory cytokines during chronic neurodegen-
ration but are “primed” to produce a more proinflammatory profile after systemic challenge with bacterial endotoxin (lipopolysaccharide
LPS]).
ethods: Here, we investigated whether intraperitoneal (IP) challenge with LPS, to mimic systemic infection, in the early stages of prion
iseasecan1)produceexaggeratedacutebehavioral (n9)andcentralnervoussystem(CNS) inflammatory (n4) responses indiseasedanimals
omparedwith control animals, and 2) whether a single LPS challenge can accelerate disease progression (n 34–35).
esults: Injectionof LPS (100g/kg), at 12weekspostinoculation (PI), resulted inheightenedCNS interleukin-1beta (IL-1), tumor necrosis
actor-alpha (TNF-), and interferon-beta (IFN-) transcription andmicroglial IL-1 translation in prion-diseased animals relative to control
nimals. This inflammation caused exaggerated impairments in burrowing and locomotor activity, and induced hypothermia and cognitive
hanges in prion-diseased animals that were absent in LPS-treated control animals. At 15weeks PI, LPS (500g/kg) acutely impairedmotor
oordination and muscle strength in prion-diseased but not in control animals. After recovery, these animals also showed earlier onset of
isease-associated impairments on these parameters.
onclusions: These data demonstrate that transient systemic inflammation superimposed on neurodegenerative disease acutely exacer-
ates cognitive and motor symptoms of disease and accelerates disease progression. These deleterious effects of systemic inflammation
ave implications for the treatment of chronic neurodegeneration and associated delirium.eyWords:Alzheimer’s disease, cytokines, delirium, inflammation,
icroglial priming, neurodegeneration, systemic
hronic neurodegeneration is accompanied by an in-
flammatory response characterized by a selective acti-
vation of the microglial cells of the central nervous
ystem (CNS) (1). This inflammation is assumed to contribute
o disease progression through the production of inflammatory
ediators. Although long-term nonsteroidal anti-inflammatory
rug (NSAID) use modestly protects against the development of
lzheimer’s disease (AD) (2), prospective studies with these
rugs in AD patients have been disappointing (3–5). This em-
hasizes the considerable gaps in our knowledge about how
icroglial activation influences chronic neurodegeneration.
Systemic infections have more severe consequences in the
lderly and demented population. Systemic infection is a com-
on trigger for episodes of delirium (6–8), and episodes of
elirium are predictive of increased morbidity and mortality
9–11). Surprisingly, direct investigations as to whether sys-
emic inflammation accelerates the progression of dementia
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oi:10.1016/j.biopsych.2008.07.024and neurodegenerative disease are lacking. Thus, whether
and how systemic inflammation and CNS disease interact to
accelerate neurodegeneration and to induce delirium is poorly
understood.
It is well known that systemic inflammation, induced by
endotoxin or proinflammatory cytokines, can induce CNS-medi-
ated behavioral responses known collectively as sickness behav-
ior (12). These include the fever response and decreased loco-
motor and reward-seeking activities and are driven by the CNS
synthesis of inflammatory mediators. We have previously shown
that sickness behavior responses to peripheral challenge with
bacterial endotoxin (lipopolysaccharide [LPS]) are exaggerated in
late-stage prion-diseased mice with chronic neurodegeneration
and associated microglial “priming” (13). This priming consists of
morphological and cell surface marker evidence of activation
(14) but minimal proinflammatory cytokine synthesis (15–17).
However, these primed hippocampal microglia undergo a phe-
notypic switch and produce a pronounced proinflammatory
profile, characterized by microglial interleukin-1 beta (IL-1),
upon systemic challenge with LPS (13,18).
In the current study, we hypothesized that a systemic inflam-
matory episode induced by bacterial endotoxin (100 g/kg) in
animals with prion disease would induce exaggerated inflamma-
tory and sickness behavioral responses and acute hippocampal-
dependent cognitive impairment, in a novel shallow water
Y-maze, that is absent upon similar challenge in normal animals
or in saline-treated prion animals. We also hypothesized that a
single systemic LPS challenge at 14 to 15 weeks postinoculation
would induce acute impairments in motor coordination and
muscle strength only in prion-diseased animals and would
accelerate or exacerbate progression of the disease.
BIOL PSYCHIATRY 2009;65:304–312
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nimals and Stereotaxic Surgery
Female C57BL/6 mice, n  233 (Harlan Olac, United King-
om), were housed in cages of five at 21°C with a 12:12 hour
ight-dark cycle (lights on 0700 to 1900) with free access to food
nd water. They were anesthetized intraperitoneally (IP) with
vertin (Sigma, Poole, United Kingdom) and positioned in a
tereotaxic frame. One microliter of a 10% wt/vol scrapie-
nfected (ME7 strain) C57BL/6 brain homogenate (or 10% wt/vol
ormal brain homogenate [NBH]) was injected into both dorsal
ippocampi (from bregma: anterior-posterior 2.5 mm, lateral
1.7 mm, depth 1.6 mm) using a microsyringe (Hamilton,
eno, Nevada). Further animals (n  9) were injected intracere-
rally (IC) with N-methyl-D-aspartate (NMDA) (10 mg/mL) to
blate the hippocampus. This surgery was performed under
soflurane anesthesia (approximately 2%) with perisurgical anal-
esia (carprophen, 5 mg/kg). Chlordiazepoxide (CDZP; 10 mg/
g) and atropine (.075 mg/kg) were given to minimize seizure
ctivity and bronchial secretions, respectively. In all other re-
pects, the hippocampal lesions were performed as previously
escribed (19). Sham-operated animals (n  12) had eight holes
rilled in the skull but no IC injections made. Female animals
ere used for all studies to minimize the occurrence of fighting,
ince this has significant effects on behavior.
ntraperitoneal Challenges
Experimental groups at 12 weeks postinoculation with ME7 or
BH were injected with 100 g/kg of LPS IP (Equine abortus
L5886], Sigma) in a volume of 200 L saline. Prior studies
emonstrated exacerbated neuronal death and floor effects on
ickness behavior with LPS at 500 g/kg (13). We thus injected
00 g/kg to examine the longitudinal effect of LPS on disease
rogression at 14 to 15 weeks (n  34–35) but injected 100
g/kg to elucidate exaggerated sickness effects at 12 weeks (n
). ME7 animals were given lower doses of LPS than NBH
nimals in Y-maze experiments (100 g/kg vs. 500 g/kg, n 
3–24) as a conservative measure, such that ME7  LPS animals
ere not more sick than the NBH  LPS animals (to verify that
ny cognitive change observed was not attributable to some
onspecific aspect of exaggerated sickness). This was verified by
pen field activity assessment (data not shown). Control animals
ere administered 200 L nonpyrogenic saline.
urrowing
Mice were placed in individual cages with a food pellet-filled,
paque plastic burrow tube as previously described (20). The
eight of pellets displaced in a 2-hour period was measured for
everal baseline sessions prior to LPS administration. On the day
f LPS challenge, mice were placed in the cages to measure
urrowing 2 hours after LPS and also at 24 and 48 hours later.
pen Field Activity
Open field activity was assessed using activity monitor soft-
are (Med Associates Inc., Georgia, Vermont) as previously
escribed (21). The open field consisted of an aluminium base
27  27cm) enclosed on four sides with a .7-cm-thick clear
crylic sheet, surrounded by an opaque screen. Animals were
ested at weekly intervals from 6 weeks postinoculation, thus
nsuring baseline stability. Locomotor activity was measured
mmediately before LPS challenge and then 5 hours and 24 hours
ollowing IP challenges.Body Temperature
A thermocouple rectal probe (Thermalert TH5, Physitemp,
Clifton, New Jersey) was used to measure core body tempera-
ture. The mice were preadapted to measurements of rectal
temperature for 2 days prior to the IP challenges to minimize
stress effects. Temperatures were taken at baseline and then at 5
hours and 24 hours postchallenge (approximately 5:00 PM and
11:00 AM).
Spatial Learning
We have developed a novel “paddling” Y-maze task to
investigate cognitive status in sick animals since reduced appet-
itive, motivational, and locomotor drives confound data from
many common tests of hippocampal function. This Y-maze task
has recently been published (22) and combines elements of two
hippocampal-dependent tasks: the paddling pool spatial cogni-
tion test and the appetitive Y-maze (23,24). Briefly, a clear
perspex Y-maze mounted on a white plastic base (constructed in
the School of Biomedical Sciences, University of Southampton)
was filled with 2 cm of water at 20°C to 22°C, sufficient to
motivate mice to leave the maze by paddling to an exit tube at
the distal end of one arm, 2 cm above the floor. The mouse exits
to a burrowing tube in which it is returned to its home cage.
Burrowing tubes were also placed over the false exit tubes so
that, from the center, all arms looked identical. The maze was
placed in the middle of a small room surrounded by prominent
visual cues. The location of the exit was fixed for each animal.
Mice were placed in one of the two possible start arms in a
pseudorandomized sequence for 10 trials and the groups were
counterbalanced with respect to the location of the exit. ME7 and
NBH mice were treated with saline or LPS and assessed, starting
3 hours postchallenge, on incorrect trials (failure to choose the
correct arm first) and total number of arms entered. An arm entry
was defined as entry of the whole body, excluding the tail. Mice
with NMDA lesions of the hippocampus and sham-operated
animals were also tested to verify hippocampal dependence of
the task.
Motor Tests: Horizontal Bar and Inverted Screen
The horizontal bar assessed forelimb muscular strength and
coordination. It consisted of a 26 cm long metal bar, .2 cm
diameter, supported by a 19.5 cm high column at each end. Each
mouse was held by the tail, placed with its front paws at the
central point of the bar, and rapidly released. A time was
assigned depending on whether and when the mouse fell, held
on for 60 seconds, or reached a supporting column (the latter
two results scoring the maximum of 60 seconds). The inverted
screen (25) assessed muscular strength for all four limbs. It
consisted of a wooden frame, 43 cm square, covered with wire
mesh (12 mm squares of 1 mm diameter wire). The mouse was
placed on the screen, which was then slowly (2 seconds)
inverted. The time it took for the mouse to fall was measured, up
to a criterion time of 60 seconds. Padding was provided to
cushion mice falling off either apparatus.
Quantitative PCR
Animals were terminally anesthetized and transcardially per-
fused with heparinized saline 2 hours postadministration of LPS
or saline. Brains were rapidly removed and the hippocampi were
dissected out, snap frozen in liquid nitrogen, and stored at
80°C. Total RNA was extracted using Qiagen RNeasy mini
columns (Qiagen, Crawley, United Kingdom) according to the
manufacturer’s instructions. Contaminating genomic DNA was
www.sobp.org/journal
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wegraded during extraction with Qiagen DNase1 (Qiagen). Two
undred nanograms of total RNA were reverse-transcribed in a
0 L reaction volume and 1 L of the reverse transcription (RT)
eaction was used for polymerase chain reaction (PCR). Equip-
ent and reagents for quantitative PCR were supplied by Ap-
lied Biosystems (Warrington, United Kingdom). Assays for
L-1, tumor necrosis factor-alpha (TNF-), and interferon-beta
IFN-) were designed using the published sequences for these
enes and Primer Express software (Applied Biosystems, War-
ington, United Kingdom) and quantified using a relative stan-
ard curve. These methods and primer sequences have been
escribed elsewhere (26) and are included in full in Supplement
. All PCR data were normalized to the expression of the
ousekeeping gene glyceraldehyde-3-phosphate dehydrogenase
GAPDH).
mmunohistochemistry
Immunohistochemistry for cyclooxygenase-2 (COX-2) and
L-1 was carried out on formalin-fixed, paraffin-embedded
ections. Sections were dewaxed, rehydrated, quenched with 1%
ydrogen peroxide (H2O2) in absolute methanol, and washed
riefly in phosphate buffered saline (PBS) before antigen re-
rieval by microwaving in citrate buffer (pH 6) for 2  5 minutes.
ections were blocked with 10% horse serum (for COX-2) or 20%
ormal goat serum (for IL-1) before overnight incubation with
he primary antibody at 1/1000 (goat polyclonal anti-COX-2,
anta Cruz Biotechnology Inc., Santa Cruz, California) or 1/50
rabbit polyclonal anti-IL-1, Peprotech, London, United King-
om) prepared in 20% serum to block nonspecific interactions.
he sections were washed and then incubated with the appro-
riate biotinylated secondary antibody. Labeling was visualized
sing the avidin-biotin-peroxidase complex (ABC method, using
015% vol/vol hydrogen peroxide as substrate and diaminoben-
idine as chromagen (Sigma) as previously described (26).
tatistical Analyses
Acute biochemical experiments were analyzed by one-way
nalysis of variance (ANOVA) with Bonferroni post hoc compar-
sons. Interaction between disease and acute treatment was
nalyzed using two-way ANOVA. All acute behavioral experi-
ents were analyzed using a planned comparison by one-way
NOVA, with Bonferroni post hoc tests, at the time predicted to
roduce clearest differences in LPS-induced effects. Parametricity
as tested by Kolmogorov-Smirnov test. Horizontal bar and
nverted screen data were nonparametric and were analyzed by
ruskal-Wallis at 6 hours post-LPS challenge and across the
ost-LPS time course by repeated measures two-way ANOVA.
he numbers reaching a criterion of 60 seconds were also
ompared by one-tailed Fisher exact test, with Tocher’s modifi-
ation. Median numbers of errors made on Y-maze acquisition
ere compared by the Kruskal-Wallis one-way ANOVA with
unn post hoc tests and also analyzed by repeated measures
NOVA to assess acquisition across two blocks of trials. Longi-
udinal effects of LPS on disease progression were assessed by
epeated measures ANOVA.
esults
cute LPS-Induced Changes at 12Weeks
At 12 weeks postinoculation, ME7 and NBH mice showed
quivalent burrowing and open field performance prior to LPS
hallenge. All treatment groups burrowed, on average, between
50 g and 170 g of pellets in baseline 2-hour sessions. Average
ww.sobp.org/journalbaseline distance travelled was between 240 cm and 330 cm for
all groups.
Burrowing
Between 2 and 4 hours postsystemic challenge with LPS, all
LPS-treated animals showed complete inhibition of burrowing
(Figure 1A). At 24 hours, there was good recovery of burrowing
in NBH  LPS animals (not significantly different from that at 0
time [baseline burrowing taken 24 hours before LPS challenge,
p  .05) but ME7  LPS animals were still impaired to approx-
Figure 1. Acute sickness behavioral responses to intraperitoneal LPS. (A)
Weight burrowed over 2 hours by C57BL/6 mice at baseline, 2 hours, 24
hours, and 48 hours post-IP challenge with 100 g/kg LPS or sterile saline.
ME7 and NBH animals were 12 weeks postinoculation with the ME7murine
scrapie strain or normal brain homogenate, respectively. Statistical signifi-
cance was determined by planned comparisons by one-way ANOVA with
Bonferroni post hoc test at 24hours. (B)Distance traveled in anopenfieldby
the same animals at baseline, 5 hours, 24 hours, and 48 hours postchallenge
with LPS. Statistical significance was determined by planned comparisons
by one-way ANOVA with Bonferroni post hoc test at 5 hours. (C) Core body
temperature of the same animals at24, 0, 5, and 24 hours postchallenge
with LPS or saline. Planned comparison by one-way ANOVA at 5 hours was
performed. All data are plotted asmean
 SEM and n 9 in all groups. *p	
.05. ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopolysaccharide;
NBH, normal brain homogenate.imately 50% (one-way ANOVA, p 	 .05). All animals returned to
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C. Cunningham et al. BIOL PSYCHIATRY 2009;65:304–312 307ormal by 48 hours. Thus, systemic inflammatory challenge
nduced a greater inhibition of burrowing in prion-diseased than
n control animals.
pen Field Activity
Lipopolysaccharide (100 g/kg) reduced locomotor activity
n both normal NBH and prion-diseased mice (Figure 1B) but this
nhibition was greater (approximately 80% vs. 50%) in ME7
nimals than NBH control animals (p 	 .05, one-way ANOVA
ith Bonferroni post hoc test at 5 hours post-LPS). Normal open
ield activity had recovered in all groups by 24 hours.
ody Temperature
It is known that LPS causes hypothermia rather than hyper-
hermia in the C57BL/6 mouse at ambient temperatures (27).
owever, small changes in body temperature are difficult to
etect using rectal probe measurements. Accordingly, LPS did
igure 2. Inflammatory changes post-LPS at 12 weeks. Relative mRNA expr
nd ME7  LPS 100 g/kg for (A) IL-1, (B) TNF-, and (C) IFN-. In all cas
isease and acute treatment by two-way ANOVA are denoted by two aster
E7  LPS and all other groups by one-way ANOVA is denoted by one a
arenchymaafter IP challengeofNBHanimalswith LPS. (E) IncreasedCOX-2
aline. (F) COX-2 positive stained cells in both the parenchyma and around
n microglial cells in the hippocampus of ME7 animals challenged IP with LPS
reated with LPS (G). Scale bar represents 100 m (D, F) and 40 m (G-I). AN
nterleukin-1 beta; IP, intraperitoneal; LPS, lipopolysaccharide;mRNA,messenger RNnot induce a measurable hypothermia at 5 hours in NBH control
animals (Figure 1C). In contrast, a clear and statistically signifi-
cant hypothermic response was observed in ME7 animals given
the same dose of LPS (p	 .05, one-way ANOVA with Bonferroni
post hoc test at 5 hours post-LPS). Thus, LPS at 100 g/kg
induces a measurable hypothermia in ME7 but not in NBH
animals.
Inflammatory Changes at 12Weeks
Expression of messenger RNA (mRNA) for the genes IL-1,
TNF, and IFN- was observed 2 hours after challenge of NBH
animals with LPS (100 g/kg). Bonferroni post hoc tests after a
significant one-way ANOVA showed that the magnitude of this
increase, for all three genes, was significantly higher in ME7
animals given the same LPS challenge (Figure 2A–C): NBH LPS
versus ME7  LPS, p 	 .001 (IL-1), p 	 .01 (TNF), and p 	 .05
(IFN-). A two-way ANOVA analysis revealed that there were, as
n for treatment groups NBH saline, NBH LPS 100 g/kg, ME7 saline,
 4 for all groups except ME7  saline (n  5). Significant interactions of
*) (IL-1 p	 .0001; TNF- p .0013) and a significant difference between
k (*). (D) COX-2 staining (brown) both around the vasculature and in the
ve cells,with respect toNBH, in theparenchymaofME7animals treatedwith
sculature of ME7 animals challenged with LPS. (G-I) IL-1 positive staining
pared with an absence of this staining in ME7 per se (H) and in NBH animals
, analysis of variance; COX-2, cyclooxygenase-2; IFN-, interferon-beta; IL-1,essio
es, n
isks (*
steris
positi
the va
(I) com
OVAA; NBH, normal brain homogenate; TNF-, tumor necrosis factor-alpha.
www.sobp.org/journal
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wxpected, clear main effects of LPS on all three genes. However,
here was also a significant interaction of disease and acute
reatment on expression of IL-1 [F (3,13) 70.49, p	 .0001] and
NF [F (3,13)  16.76, p  .0013], whereas that for IFN- was
ot quite significant [F (3,13)  3.54, p  .0825]. Microglial
ctivation was apparent in all ME7 animals as evidenced by
ncreased numbers of microglial cells positively stained for
OX-2 in the hippocampus compared with that in NBH animals
Figure 2D–F). As previously observed (18), COX-2 staining was
lso observed constitutively in perivascular macrophages and
nducibly in endothelial cells after LPS challenge. Phenotypic
witching of microglia to the more proinflammatory state is
anifest as increased IL-1 staining in ME7  LPS animals
ompared with NBH  LPS animals, which do not show detect-
ble microglial IL-1 staining (Figure 2G-I). Interleukin-1 beta
ositive microglia were found proximal to hippocampal blood
essels, but we cannot rule out the possibility of IL-1 that is
elow the limit of detection in NBH LPS animals or deeper into
he parenchyma of ME7  LPS animals.
patial ReferenceMemory in the Y-Maze
Normal brain homogenate and ME7 animals were treated with
aline or LPS (n  23 for NBH, n  24 for ME7) and tested in the
isuospatial reference memory paddling Y-maze, between 3 and
hours, to test for LPS-induced learning impairments. The ME7
nimals challenged with LPS made more incorrect arm entries
cross 10 trials than any of the other groups (Figure 3A; p	 .0001
ruskal-Wallis test). Dunn’s multiple comparison post hoc tests
evealed ME7  LPS animals to be significantly different from all
ther groups (p 	 .05). Plotted as the average number of arms
ntered, in two blocks of five trials (Figure 3B), ME7  LPS
nimals made considerably more errors in block 1 and this
ersisted to a lesser degree in block 2. These animals were
ypoactive at this time, so increased arm entries cannot be
xplained by increased activity. Despite the sickness of the
BH LPS animals, their learning was not significantly impaired
ompared with NBH  saline animals (Figure 3B). This simple
-maze has been designed to allow learning to be achieved in a
ingle session, while LPS effects persist, to eliminate state-
ependent effects. Thus, comparison of block 2 with block 1
paired t tests p 	 .0013) is suggestive of some learning in all
roups. Repeated measures ANOVA comparison of arm entries
y ME7  LPS and ME7 animals shows main effects of treatment
F  9.66, p  .0032, df  1,46) and of trial (F  9.9, p 	 .0001,
f  9,414) but that for NBH  saline and NBH  LPS shows an
ffect of trial (F  24.88, p 	 .0001, df  9,396) but no effect of
reatment (F  1.62, p  .2091, df  1,44). Thus, LPS has no
mpact on the accuracy of NBH animals in this maze task but
oes impair that of ME7 animals.
Acquisition of correct responding in this maze was hippocam-
al-dependent (Figure 3C). Sham-operated animals quickly
earned the location of the exit while hippocampal-lesioned
nimals continued responding at chance levels (50%). A repeated
easures ANOVA analysis shows a significant effect of treatment
F  10.78, p  .0039, df  1,19).
cute LPS-Induced Changes at 15Weeks
Horizontal Bar and Inverted Screen. All animal groups per-
ormed the horizontal bar task well at 14 weeks (Figure 4A).
pon IP challenge with LPS, ME7 animals showed a decrease in
erformance relative to the NBH  LPS group. Repeated mea-
ures ANOVA reveals an interaction of time and treatment (F 
.05, p  .0085, df  6,114) and Bonferroni post hoc test at 6
ww.sobp.org/journalhours reveals significant impairment of ME7  LPS (p 	 .05).
ME7  saline animals performed well throughout the experi-
Figure 3. Spatial learning in the paddling Y-maze: normal and prion-dis-
eased animals and hippocampal-lesioned and sham-operated control ani-
mals. (A) Cognitive performance of animals in the paddling Y-maze at 12
weeks postinoculation with ME7 (100 g/kg LPS or saline) and NBH (500
g/kg LPS or saline) 3 to 7 hours after IP challenge. This plot represents the
total number of incorrect trials (out of 10) by each treatment group. Each
animal is shown as an individual point and the median is illustrated by the
bar. Kruskal-Wallis ANOVA revealed a difference in the medians (p	 .0001)
andpairwise comparisons showedME7 LPS tobe significantly different to
all other groups (**), n 23 in the case of both NBH groups and n 24 for
bothME7 groups. (B) The same data are plotted as two successive blocks of
five trials, showing the average number of arms entered including the final
correct one. Block 2 is compared with block 1 by Student t tests in all cases
(*p 	 .05). The average number of arms entered in block 1 by each group
was also compared byANOVAwith Bonferroni post hoc test (*p	 .05, **p	
.01). (C) Hippocampal-lesioned animals compared with sham-operated
control animals tested across two blocks of five trials on the same paddling
Y-maze. A repeated measures ANOVA analysis shows a significant effect of
treatment (F 10.78, p .0039, df 1,19) and of trial (F 3.54, p .0005,
df  9,171). ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopoly-
saccharide; NBH, normal brain homogenate.ment. Since the data were nonparametric, a scatter dot plot is also
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C. Cunningham et al. BIOL PSYCHIATRY 2009;65:304–312 309hown (Figure 4B). Nine out of 12 NBH  LPS animals reached
criterion of 60 (median  60), while 9 out of 14 ME7  LPS
nimals failed to reach this criterion (median  38). The propor-
ions of each group that reached criterion are significantly
ifferent by one-tailed Fisher exact test with Tocher’s modifica-
ion. Furthermore, when the times are compared by Kruskal-
allis, with a Dunn post hoc test, ME7 LPS and NBH LPS are
ignificantly different (p 	 .05).
All animal groups showed good performance on the inverted
creen at 14 weeks (Figure 4C). Lipopolysaccharide induced a
lear decrease in times in ME7 animals compared with the same
hallenge in NBH animals and to saline challenges in ME7
nimals (Bonferroni post hoc test at 6 hours, p 	 .001). This
ecrease is most obvious at 6 hours but is still apparent at 24
ours and repeated measures ANOVA reveals a main effect of
reatment (F  5.35, p  .0088, df  2,39) and an interaction of
ime and treatment (F  4.49, p  .0004, df  6,117). We also
rovide scatter dot plots of the 6-hour data (Figure 4D). When
hese data are compared by Kruskal-Wallis, with Dunn post hoc
ests, there is a statistically significant difference between ME7 
PS and NBH  LPS (p 	 .05).
All groups showed good recovery on both tasks by 15 weeks.
hese data demonstrate a greater acute effect of LPS on motor
oordination and muscle strength in ME7 animals than in NBH
ontrol animals. When administered at 12 weeks postinoculation
ith prion disease, LPS did not have any acute effects on motor
igure 4.Acute effects onmotor tasks inducedby LPS in normal andprion-d
ith ME7 or NBH, followed by performance at 6 hours, 24 hours, and 1 week
smean
 SEM and analyzed by repeatedmeasures ANOVABonferroni pos
B) Replot of the 6-hour post-LPS time point showing themedian and full ra
oc test (*p	 .05). (C) Performance on an inverted screen at the same time p
epeatedmeasures ANOVAwith Bonferroni post hoc test (p	 .001 between
creen 6-hour post-LPS time point showing the median and full range of va
*p	 .05). ANOVA, analysis of variance; IP, intraperitoneal; LPS, lipopolysaccoordination or muscle strength (data not shown).Longitudinal Effects of Systemic Infection on
Disease Progression
As previously shown, there is a clear impairment in perfor-
mance on the horizontal bar and the inverted screen in the ME7
groups between 16 and 20 weeks (Figure 5). ME7 animals
challenged with 500 g/kg LPS between 14 and 15 weeks
subsequently showed more impairment on the horizontal bar
than ME7  saline animals, and their performance on this task
remained worse throughout the experiment (Figure 5A). A
repeated measures ANOVA analysis of the two ME7 groups
revealed main effects of treatment (F  6.04, p 	 .05, df  1,65)
and of time (F  43.77, p 	 .0001, df  4,260) and an interaction
of treatment and time (F  3.06, p 	 .05, df  4,260).
ME7 animals challenged with 500 g/kg LPS between 14 and
15 weeks also subsequently showed an earlier onset of impair-
ment on the inverted screen than ME7  saline animals, and this
performance remained worse than that for ME7  saline animals
throughout the experiment (Figure 5B). A repeated measures
ANOVA analysis of the two ME7 groups revealed main effects of
treatment (F  6.41, p 	 .05, df  1,47) and of time (F  53.86,
p 	 .0001, df  4,188) and an interaction of treatment and time
(F  2.76, p 	 .05, df  4,188).
ME7 animals challenged with LPS 500 g/kg between 14 and
15 weeks also subsequently showed an earlier decrease in open
field locomotor hyperactivity. Hyperactivity of both ME7 groups
relative to NBH control animals is clear in Figure 5C, but this is
d animals. (A)Performanceon ahorizontal bar at 14weeks postinoculation
IP LPS (500g/kg) or saline challenges in these animals. Data were plotted
ests (p	 .05 betweenME7 LPS andNBH LPS, n 13–15 for all groups).
f values. These data were compared by Kruskal-Wallis test with Dunn’s post
as described above. Data are shown asmean
 SEM andwere analyzed by
 LPS and NBH LPS, n 13–15 for all groups). (D) Replot of the inverted
These data were compared by Kruskal-Wallis test with Dunn’s post hoc test
e; NBH, normal brain homogenate.isease
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lues.less marked in the ME7 LPS group, suggesting the beginning of
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www.sobp.org/journalthe late-stage decline. Repeated measures ANOVA analysis of the
two ME7 groups shows a main effect of time (F  12.86, p 	
.0001, df  6,228) and a main effect of treatment (F  9.15, p 
.0044, df  1,38).
All of these LPS-induced decrements are temporally separated
from the acute LPS effects on these tasks shown in Figure 4 (A,B)
and together these data demonstrate that a single, transient,
peripheral inflammatory event can hasten the disease process,
accelerating the appearance of three different neurological signs
of disease.
Discussion
In the current study, we have shown that systemic LPS during
presymptomatic chronic neurodegenerative disease can induce
exaggerated CNS inflammation and sickness behavior responses
compared with those in normal animals. Acute symptoms also
now extend beyond the typical spectrum of sickness behavior
responses to include exacerbation of symptoms more commonly
associated with the underlying disease: acute cognitive impair-
ments (LPS at 12 weeks) and acute impairments of motor
coordination and muscle strength (LPS at 15 weeks). In addition,
a single LPS challenge accelerates and exacerbates the progres-
sion of the underlying disease. Thus, on multiple levels, systemic
inflammation impacts negatively on chronic neurodegeneration.
Exaggerated Sickness Behavior andMicroglial Priming
We had previously shown that at 18 weeks postinoculation
with the ME7 strain of prion disease, these animals were suscep-
tible to exaggerated sickness behavior responses to LPS (13).
Such responses were absent at 8 weeks postinoculation, before
large numbers of microglia become activated. Thus, microglia
that are activated by the process of neurodegeneration (18,28) or
aging (29,30) but which do not synthesize robust levels of
proinflammatory cytokines are susceptible to phenotypic switch-
ing by systemic inflammatory insults. We demonstrated IL-1
synthesis specifically in ME7 hippocampal microglial cells after
systemic LPS challenge but not in NBH  LPS animals or in ME7
animals injected with saline, despite marked neurodegeneration
and extracellular prion protein (PrPSc) deposits in the latter (18).
In the current study, we have shown that this phenotypic
switching, heightened cytokine production, and exaggerated
sickness behavior are also induced at 12 weeks postinoculation
with prion disease in the absence of neuronal loss but at the
onset of hippocampal CA1 synaptic loss and hippocampal-
dependent impairments (31,32). This, therefore, places subjects
at risk of disease exacerbation from an early or even presymp-
tomatic stage of disease. Whether the switch from the primed
state to that expressing IL-1 is key to this disease exacerbation
remains to be established, but given the high sensitivity of IL-1
type I receptors (33), neuroanatomically defined, microglial
IL-1 protein expression constitutes a biologically significant
event.
Acute Cognitive Impairments
Lipopolysaccharide induced acute cognitive impairments in
ME7 animals but not in NBH animals. Primed microglial cells are
limited to the hippocampus and limbic system at this stage of
disease (18,31), and therefore we hypothesized that hippocam-
pal-dependent tasks would be sensitive to these insults. We have
shown here that correct responding in the Y-maze spatial
reference memory task is hippocampal-dependent. Thus, we
have induced an acute memory deficit in LPS-treated ME7igure 5. Longitudinal effects of LPS at 14 to 15weeks on theprogression of
rion disease. (A) Performance on the horizontal bar for 6 successive weeks
ost-IP challengewith LPS (500g/kg) or saline at 15weekspostinoculation
ith ME7 or NBH. Data are shown as mean
 SEM (n 25 for NBH LPS,
 34 for ME7 Saline, and n 35 for ME7 LPS). ME7 LPS andME7
aline data were compared by repeated measures ANOVA across the 6
eeks shown and showed both main effects of treatment and time and an
nteraction of treatment and time (* denotes p .0166 for themain effect of
reatment). (B) Performance of the same animals on the inverted screen for
successiveweekspost-IP challengewith LPS (500g/kg) or saline.Data are
hown asmean
 SEM (n 25 for NBH LPS, n 34 for ME7 Saline, and
 35 forME7 LPS).ME7 Saline andME7 LPSdatawere comparedby
epeated measures ANOVA across the 5 weeks shown and showed both
ain effects of treatment and timeandan interactionof treatment and time
** denotes p  .0147 for the main effect of treatment). (C) Open field
ctivity for 7 successive weeks post-IP challenge with LPS 500 g/kg. Data
re shown as mean
 SEM (n 19, n 20). Repeated measures ANOVA of
E7 groups showed main effects of time and treatment (* denotes p 
0044 for the main effect of treatment). ANOVA, analysis of variance; IP,
animals that is hippocampal-dependent and is absent in LPS-
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C. Cunningham et al. BIOL PSYCHIATRY 2009;65:304–312 311reated NBH animals, despite obvious sickness behavior. Lipo-
olysaccharide is reported to affect cognitive function in young
nd aged mice (34–37), but there are potential confounding
actors in these studies, directly referred to by the authors. The
ovel shallow water Y-maze task developed here assesses
ncorrect responses rather than time taken to solve the maze,
hus minimizing such confounding factors. The cognitive impair-
ent that we describe upon acute inflammatory insult during
hronic neurodegeneration and similar impairments reported in
ged animals challenged with LPS (38,39) have parallels with the
cute cognitive impairments seen in episodes of delirium during
ementia. Delirium is an acute and transient confusional state
hat commonly occurs after infection, surgery, or injury (40).
elirium is remarkably prevalent in the aged and demented
opulation: 10% of over 65s admitted to the emergency room
41) and 22% to 89% in demented patients (42). The etiology of
elirium is unknown and given its very high frequency in aged
nd demented populations, it is a major research question. The
ovel Y-maze easily distinguishes between sham and hippocam-
al-lesioned animals. Larger group sizes are required to distin-
uish between ME7 and ME7  LPS animals, reflecting interani-
al variability in the onset of cognitive changes in ME7 animals.
his mirrors the difficulties in distinguishing chronic and acute
mpairments in dementia and delirium. We propose that further
efinement of the model system used here will be useful in the
tudy of how systemic inflammation and underlying dementia
nteract to produce these episodes.
cute Exacerbation Leads to Acceleration of Chronic Disease
Dementia is the single biggest risk factor for episodes of
elirium and systemic inflammation is a major trigger in these
atients. It is also now clear that a single episode of delirium is
redictive of an accelerated rate of clinical decline in demented
atients (9–11). This implies that the insults that induce episodes
f delirium are also responsible for an acceleration of the disease
rocess. We previously showed that a single challenge with LPS
as sufficient to exacerbate neuronal death during prion disease
18). Repeated challenges with LPS have been shown to exacer-
ate axonal damage and disease progression in a transgenic
odel of amyotrophic lateral sclerosis (43). Similarly, there is
vidence for exacerbation of features of pathology in a triple
ransgenic model of Alzheimer’s disease (44) and for exacerba-
ion of inflammation (45) and amyloid deposition (46) in AD
odels. In the current study, we have shown that a single
hallenge with LPS is sufficient to accelerate and exacerbate
ermanent loss of neurological function. We observed acute
mpairments of motor function during the systemic inflammatory
pisode, recovery of normal function postinflammation, and
ccelerated onset of progressive and permanent neurological
hanges. This mirrors the accelerated cognitive decline of de-
ented patients after recovery from acute symptoms of delirium
47) and indicates that systemic inflammatory insults accelerate
isease progression. It is of note that LPS administered at 12
eeks postinoculation with prion disease did not affect motor
oordination, consistent with the idea that as pathology becomes
ore global, later in disease, the range of functions that may be
ffected by systemic inflammation becomes broader. It is of
nterest to examine whether pathology and behavioral symptoms
n Tg2576 and CRND8 mice are similarly affected by systemic
nflammation. However, that our hypothesis and the current
odel have validity in human neurodegenerative disease has
een demonstrated in recent and ongoing clinical studies: carer-
eported systemic infection and elevated concentrations of IL-1in sera were independently associated with accelerated cognitive
decline in Alzheimer’s disease patients (48).
Conclusion
We have shown a clear systemic inflammation-induced exac-
erbation of neurodegenerative disease. The mechanism of this
exacerbation remains unclear. It is well known that peripheral
inflammation can activate CNS centers by a number of routes,
including the circumventricular organs, vagal afferents, and the
brain endothelium (see 12 for review). Bacterial endotoxin can
directly activate the brain endothelium (49,50), but it is well
known that behavioral and CNS inflammatory changes can be
induced by systemic administration of proinflammatory cyto-
kines (12). Furthermore, it has recently been shown that systemic
IL-1 exacerbates neurodegeneration and motor symptoms in a
rat model of Parkinson’s disease (51). Due to the large numbers
of animals required to overcome interindividual variability in the
current study, mechanistic analysis was impractical. However,
preliminary investigations in normal animals show that indo-
methacin does not inhibit CNS proinflammatory cytokine tran-
scription despite clear effects on LPS-induced behavioral changes
and on prostaglandins (52). There remain many unanswered
questions about the nature of the interactions between systemic
and CNS inflammatory compartments in this model and in
human disease. Studies addressing these interactions and the
relative roles of endotoxin, cytokines, and prostaglandins will
have implications for our understanding of the role of inflamma-
tion in neurodegenerative disease and in episodes of delirium.
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